Drs. Alexander and Witteles discuss emerging data on transthyretin amyloid cardiomyopathy therapies, emphasizing early initiation of disease-modifying treatment and the prognostic value of functional measures such as the six-minute walk test. They also highlight observational evidence that aggressive cardiometabolic management, including use of newer antidiabetic agents, may further reduce residual cardiovascular risk in patients with ATTR-CM and diabetes.

Drs. Montesi and Martinez explore how to define and monitor PPF, especially in non-IPF ILD. They describe advances in recognizing progression and the use of antifibrotic therapy, while also highlighting ongoing controversy over exact criteria and emphasizing the need to combine symptoms, lung function (FVC, DLCO), and CT imaging for careful, regular follow-up.

This episode reviews the ongoing Cyclospora outbreak and emphasizes the importance of targeted diagnostic testing for patients with persistent summer diarrhea, highlights evidence supporting family-based behavioral treatment for childhood obesity in primary care, and examines a new meta-analysis comparing the cardiometabolic benefits of GLP-1 receptor agonists beyond weight loss. Together, these studies reinforce practical, evidence-based approaches to infectious disease, pediatric obesity, and personalized obesity management.

Drs. Garg and Mehta focus on challenges and solutions in providing retinal care for patients—especially those with diabetes—including barriers like socioeconomic factors, transportation, insurance, and the need for coordinated, team-based care with other medical specialists. They highlight initiatives such as diabetic eye screening days and emerging technologies like tele-ophthalmology, home OCT, and AI-driven screening and monitoring to improve access, continuity of care, and visual outcomes.

Drs. Bunick and Shahriari discuss the emerging role of the OX40/OX40L pathway in atopic dermatitis, highlighting how targeting antigen-specific T cells may rebalance the immune system and potentially induce durable, off-drug remission. They review promising phase 2 and 3 data for agents like rocatinlimab and amlitelimab, emphasize encouraging safety profiles, and explore future innovations such as combination and bispecific approaches to improve both speed and durability of disease control.

Drs. Berger and Denny discuss modern secondary prevention after non-cardioembolic ischemic stroke, focusing on short dual antiplatelet courses and individualized agent choice. They emphasize structured vascular risk management and look ahead to newer, safer antithrombotic options.

Drs. Chang and Cohen discuss how MRD has become an important tool for assessing how well patients with CLL respond to treatment, beyond what standard blood tests can show. They conclude that although MRD is very useful in research and can help inform conversations with patients, it is not yet clear how or whether it should routinely guide real-world treatment decisions.

This episode reviews new evidence supporting extended DAPT beyond one year for selected patients after multivessel PCI, the role of MRD-guided decisions for maintenance lenalidomide in multiple myeloma, adjuvant ensartinib for resected ALK-positive NSCLC, and emerging data on semaglutide and combination therapy for MASH-related cirrhosis. The studies highlight how precision medicine continues to refine treatment duration, biomarker-driven care, and therapeutic selection across multiple specialties.

This episode reviews new evidence on online GLP-1 prescribing practices, aspirin-only thromboprophylaxis after hip and knee arthroplasty, unexpected protection against gonorrhea from meningococcal B vaccination, and a cannabinoid formulation for agitation in advanced dementia. The studies highlight evolving approaches to obesity care, postoperative management, infectious disease prevention, and palliative dementia treatment with important implications for clinical practice.

Drs. Martinez and Montesi discuss how treatment for ILD, IPF, and PPF has shifted from “nothing we can do” to a complex, rapidly expanding toolbox that now includes multiple antifibrotic options and emerging combination strategies. They stress that these drugs slow progression but don’t cure disease, so real-world decisions hinge on side effects, quality of life considerations, patient goals, and the often frustrating realities of insurance coverage and cost.